Celgene acquired by Bristol-Myers Squibb
Bristol-Myers Squibb acquired Celgene, a US therapeutics brand.
Preliminary: The deal status, value basis and value notes are not yet independently verified.
Transaction summary
- Target
- Celgene
- Acquirer
- Bristol-Myers Squibb
- Seller
- -
- Announced
- -
- Geography
- United States
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-10-08
- Latest update
- 2026-10-29
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed | USD
Basis: Source not stated
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Enterprise value is unavailable.
Source summary
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
ConfirmedBristol Myers Squibb’s official release verifies completion of its Celgene acquisition on November 20, 2019. The Financial Times reported a $90bn deal headline.
Open sourceBristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
ConfirmedBristol Myers Squibb’s official release verifies completion of its Celgene acquisition on November 20, 2019. The Financial Times reported a $90bn deal headline.
Open sourceContinue your research
Related transaction comps
Edgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction → BiotechMyricx Bio acquired by Novartis
2026-07-06 · Confirmed
View transaction → Biotech4E Therapeutics acquired by Eli Lilly and Company
2026-06-16 · Confirmed
View transaction → BiotechXOMA acquired by Ligand
2026-04-27 · Confirmed
View transaction →